LESCOL
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LESCOL by Novartis is hmg-coa reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) to mevalonate, a precursor of cholesterol. First approved in 1993.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LESCOL (fluvastatin) is an oral HMG-CoA reductase inhibitor (statin) approved in 1993 that lowers cholesterol by blocking the rate-limiting enzyme in cholesterol synthesis. It is indicated for patients with elevated LDL cholesterol to reduce cardiovascular risk. The drug represents the foundational statin class mechanism that revolutionized lipid management.
LOE Approaching
As a legacy statin facing LOE, the brand team is likely small and focused on retention and cost management rather than growth initiatives.
Mechanism of Action
HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LESCOL roles are primarily in defensive commercial and market access functions rather than growth-oriented functions. Career development on this product is limited; positions tend to focus on generic containment, formulary retention, and compliance with pricing regulations.
Brand ManagerField Sales Representative
Worked on LESCOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.